320 related articles for article (PubMed ID: 27521276)
1. Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas.
Malysz J; Erdman P; Klapper J; Zhu J; Creer M; Bayerl MG
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):429-33. PubMed ID: 27521276
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
[TBL] [Abstract][Full Text] [Related]
3. CD30 expression and survival in posttransplant lymphoproliferative disorders.
Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
[No Abstract] [Full Text] [Related]
4. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma.
Badri N; Ngamdu KS; Torabi A; Guar S
J Cancer Res Ther; 2020; 16(1):183-185. PubMed ID: 32362635
[TBL] [Abstract][Full Text] [Related]
6. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
7. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity.
Schwartz Z; Bowe RB; Coleman M; Magro CM
Ann Diagn Pathol; 2018 Dec; 37():57-61. PubMed ID: 30292067
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
[TBL] [Abstract][Full Text] [Related]
9. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
[TBL] [Abstract][Full Text] [Related]
10. Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.
Albany C; Einhorn L; Garbo L; Boyd T; Josephson N; Feldman DR
Oncologist; 2018 Mar; 23(3):316-323. PubMed ID: 29222199
[TBL] [Abstract][Full Text] [Related]
11. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
12. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Bhatt G; Maddocks K; Christian B
Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
[TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous follicle center lymphoma with diffuse CD30 expression: a report of 4 cases of a rare variant.
Kempf W; Kazakov DV; Rütten A; Rupec RA; Talarcik P; Ballová V; Kerl K; Dummer R; Lautenschlager S; Zimmermann DR; Tinguely M
J Am Acad Dermatol; 2014 Sep; 71(3):548-54. PubMed ID: 24836545
[TBL] [Abstract][Full Text] [Related]
14. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
Nizamuddin I; Galvez C; Pro B
Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.
Kim M; Lee JO; Koh J; Kim TM; Lee JY; Jeon YK; Keam B; Kim DW; Lee JS; Heo DS
Haematologica; 2021 Aug; 106(8):2277-2280. PubMed ID: 33792222
[No Abstract] [Full Text] [Related]
16. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.
Kawamoto K; Miyoshi H; Suzuki T; Sasaki Y; Yamada K; Yanagida E; Muto R; Kiryu M; Sone H; Seto M; Ohshima K; Takizawa J
Hematol Oncol; 2018 Feb; 36(1):166-173. PubMed ID: 29052238
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy.
Gopal AK; Bartlett NL; Forero-Torres A; Younes A; Chen R; Friedberg JW; Matous JV; Shustov AR; Smith SE; Zain J; O'Meara MM; Fanale MA
Leuk Lymphoma; 2014 Oct; 55(10):2328-34. PubMed ID: 24359243
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
19. Fibrin-associated EBV-positive Large B-Cell Lymphoma: An Indolent Neoplasm With Features Distinct From Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation.
Boyer DF; McKelvie PA; de Leval L; Edlefsen KL; Ko YH; Aberman ZA; Kovach AE; Masih A; Nishino HT; Weiss LM; Meeker AK; Nardi V; Palisoc M; Shao L; Pittaluga S; Ferry JA; Harris NL; Sohani AR
Am J Surg Pathol; 2017 Mar; 41(3):299-312. PubMed ID: 28195879
[TBL] [Abstract][Full Text] [Related]
20. Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy.
Sotomayor EM; Young KH; Younes A
Clin Adv Hematol Oncol; 2014 Apr; 12(4 Suppl 10):1-22. PubMed ID: 24870054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
